ENCell Co., Ltd. (KOSDAQ:456070)

South Korea flag South Korea · Delayed Price · Currency is KRW
16,720
+20 (0.12%)
Feb 19, 2026, 1:50 PM KST
Market Cap183.11B -11.9%
Revenue (ttm)5.91B -44.9%
Net Income-17.78B
EPS-1,643.13
Shares Out10.96M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume134,351
Average Volume496,318
Open16,700
Previous Close16,700
Day's Range16,360 - 16,860
52-Week Range10,000 - 22,800
Betan/a
RSI50.62
Earnings Daten/a

About ENCell

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456070
Full Company Profile

Financial Performance

In 2024, ENCell's revenue was 7.21 billion, a decrease of -31.51% compared to the previous year's 10.53 billion. Losses were -15.21 billion, 201.0% more than in 2023.

Financial Statements